Wasteful and Inappropriate Service Reduction Model (WISeR)
Model Summary
1. Executive Summary and Strategic Context
The Wasteful and Inappropriate Service Reduction (WISeR) Model represents the first large-scale deployment of artificial intelligence and machine learning in Medicare fee-for-service prior authorization. Launching January 1, 2026, WISeR introduces mandatory prior authorization and pre-payment review for 15-17 targeted outpatient services across six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington, covering four Medicare Administrative Contractor (MAC) jurisdictions.
WISeR is a six-year model (January 1, 2026 through December 31, 2031) operating under CMS Innovation Center Section 1115A authority. Unlike traditional CMMI payment models that restructure reimbursement, WISeR fundamentally alters the claims adjudication process by inserting AI-driven prior authorization intermediaries between providers and Medicare payment. CMS estimates that targeted services represent $1.9-5.8 billion in annual spending on low-value care, with skin substitutes alone exceeding $10 billion in Medicare Part B spending in 2024.
1.1 Strategic Significance
WISeR is simultaneously a fraud prevention initiative, an AI deployment pilot, and a political lightning rod. It imports Medicare Advantage-style prior authorization into fee-for-service Medicare for the first time at scale, using third-party technology vendors as decision intermediaries. The model has generated significant congressional opposition, with House legislation introduced to block implementation and Appropriations Committee amendments to defund it. The American Hospital Association and multiple specialty societies have raised concerns about care access delays.
For providers in affected states, WISeR creates an immediate operational burden requiring new workflows, documentation standards, and revenue cycle processes. For the broader healthcare industry, WISeR serves as a proof-of-concept for AI-driven utilization management that could expand nationally if deemed successful.
2. Model Architecture and Regulatory Framework
2.1 Legal Authority and Publication History
WISeR was authorized under Section 1115A of the Social Security Act, with the following regulatory timeline:
Public Announcement: June 22, 2025, CMS announced the WISeR Model.
Federal Register Notice: Published July 1, 2025 (Document 2025-12195). Notice titled 'Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model.' Signed by CMS Administrator Dr. Mehmet Oz.
RFA Application Deadline: July 25, 2025 for technology vendor participants.
Model Participants Announced: November 6, 2025. Six technology companies selected: Cohere Health Inc., Genzeon Corporation, Humata Health Inc., Innovaccer Inc., Virtix Health LLC, and Zyter Inc.
Effective Date: January 1, 2026.
2.2 Geographic Scope and MAC Jurisdiction Mapping
| State | MAC Jurisdiction | Technology Vendor | Selection Criteria |
|---|---|---|---|
| New Jersey | JL | Assigned vendor | Existing skin substitute LCDs |
| Ohio | J15 | Assigned vendor | High volume of targeted services |
| Oklahoma | JH (shared with TX) | Assigned vendor | Geographic diversity |
| Texas | JH (shared with OK) | Assigned vendor | Highest historical claim paid amounts |
| Arizona | JF (shared with WA) | Assigned vendor | MAC without skin substitute LCDs (generalizability) |
| Washington | JF (shared with AZ) | Assigned vendor | Within-MAC comparison capability |
Selection criteria included both evaluability factors (within-MAC comparisons, adequate volume for statistical precision, geographic diversity) and operational factors (existing LCD coverage, highest historical claim volumes).
2.3 Model Duration and Agreement Periods
WISeR operates in two three-year agreement periods:
Agreement Period 1: January 1, 2026 through December 31, 2028
Agreement Period 2: January 1, 2029 through December 31, 2031
CMS reserves the right to add additional services in future years and may expand geographic scope based on initial results.
3. Targeted Services and Coverage Determinations
WISeR targets 15-17 outpatient services deemed vulnerable to fraud, waste, and abuse. Services were selected based on: non-emergent status, existing prior authorization by other payers (including MA plans), publicly available Medicare coverage requirements, and documented patterns of overuse or improper billing.
3.1 Initial Service Categories
| Service Category | NCD/LCD References | Risk Profile |
|---|---|---|
| Skin and Tissue Substitutes | L35041, L36690 (where active LCD exists) | $10B+ Part B spending 2024; HHS OIG flagged |
| Electrical Nerve Stimulator Implants | Multiple LCDs | Device-related fraud patterns |
| Epidural Steroid Injections (excl. facet joint) | LCD-based | High volume, overuse documented |
| Percutaneous Vertebral Augmentation (PVA) | L34106, L38201, L35130 | Compression fracture treatment |
| Percutaneous Image-Guided Lumbar Decompression | LCD-based | Spinal stenosis treatment |
| Cervical Fusion | L39741, L39762, L39793 | Excludes codes in OPD PA process |
| Knee Arthroscopy for Osteoarthritis | NCD 150.9 | Low clinical evidence for OA indication |
| Hypoglossal Nerve Stimulation (OSA) | L38276, L38307, L38398, L38387, L38310, L38312, L38385, L38528 | Obstructive sleep apnea device |
| Incontinence Control Devices | LCD-based | Utilization management target |
| Impotence Treatments | LCD-based | Utilization management target |
Critical exclusions: Inpatient-only services, emergency services, and services where delay could pose substantial risk to patients are excluded from WISeR prior authorization requirements.
4. Prior Authorization Process and Workflow
4.1 Submission Pathways
Providers and suppliers have two pathways under WISeR:
Pathway 1 - Prior Authorization (Recommended): Submit PA request to either the MAC or the WISeR technology vendor with supporting clinical documentation before rendering the service. Vendor reviews using AI/ML tools and provides determination within 3 calendar days (standard) or 2 calendar days (expedited/urgent). Affirmation guarantees Medicare payment upon proper billing.
Pathway 2 - Render Without PA (Permitted but Risky): Provider furnishes the service without PA. Claim is then subject to mandatory pre-payment medical review by the WISeR vendor, with 45 days to provide requested documentation. Higher documentation burden and payment delay risk.
4.2 Decision Framework
The WISeR AI/ML review evaluates whether the proposed service meets all applicable Medicare coverage, coding, and payment requirements, including relevant National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and general Medicare billing standards.
Affirmed: Service meets Medicare requirements. Provider may proceed and submit claim with confidence of payment.
Non-Affirmed: Service does not meet coverage requirements as documented. Critical protections: unlimited resubmissions permitted, peer-to-peer review available, non-affirmation does NOT prevent service delivery, full Medicare appeals process preserved.
Human Clinician Review: All denial decisions must be reviewed by a licensed clinician with relevant expertise. AI alone cannot issue a final denial.
4.3 Vendor Compensation Model
WISeR technology vendors are compensated based on a percentage of the dollar value of denied requests after all resubmissions have been adjudicated. This 'averted expenditures' payment model is novel and has raised significant concerns about misaligned incentives, as vendors may financially benefit from higher denial rates. CMS has stated vendors are incentivized to 'get the determination right' rather than to deny claims, but the structural incentive warrants close monitoring.
4.4 Gold Carding Exemption
CMS plans to pilot a 'gold carding' feature by mid-2026, modeled on existing OPD prior authorization program exemptions. Providers achieving a provisional affirmation rate of 90% or higher during designated performance review periods may be granted exemption from future prior authorization requirements. Exemption can be withdrawn if claims review indicates deterioration in billing compliance.